TRANSEUROPE: Predicting outcome and developing new therapeutic strategies for haematological stem cell transplant recipients using in vitro techniques

• Research unit: EU RFP
• Project number: 03.0022

Key words (English)

Biotechnology; Environmental Protection; Innovation; Technology Transfer; Life Sciences; Medicine; Health; Waste Management

Alternative project number (English)

EU project number: QLK3-CT-2002-01936

Research programs (English)

EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'

Short description (English)

See abstract

Further information (English)

Full name of research-institution/enterprise:
Hôpitaux universitaires de Genève HUG
Département de Dermatologie

Abstract (English)

Allogeneic stem cell transplantation (SCT) is the only means of cure for haematological malignancies, as well as congenital anaemias and immunodeficiency disorders. The current poor rate of survival (30-50%) is due to post transplant complications, including infectious episodes, relapse (a lack of a graft versus leukaemia (GvL) effect) and graft versus host disease (GvHD). Tools to predict acute and chronic GvHD and/or GvL following different types of allogeneic SCT would enable new clinical protocols and therapeutics strategies to be developed based on individual patient expected risk. By the use of in vitro biotechnology. Genetic and clinical risk assessments, we aim to predict outcome following therapy and SCT; develop new Europe-wide common clinical protocols and improve current therapeutic strategies. The project involves the development of an important Europe-wide tissue bank for research use within the transplant community.

References in databases (English)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 03.0022